
News|Articles|August 1, 2025
New Data Reveals What’s Behind Delays and Denials in RA Care
This whitepaper presents a structured analysis of prior authorization outcomes for RA treatments requiring medical benefit coverage. It examines real-world access barriers from the perspective of payer decision patterns, documentation requirements, site of care, and plan type. Unlike claims-based studies or survey-based research, this analysis draws from actual prior authorization cases, providing a direct window into the real-world challenges faced by prescribers and patients alike.
Trending on PharmExec
1
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
2
Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D
3
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory
4
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
5